Lyssikatos Joseph P

CSO Joseph Lyssikatos sells 132,500 shares for $3.5M at ELVN; blended avg $26.23, stock now $25.03; company unprofitable (-$20.1M net income).

Joseph Lyssikatos, Chief Scientific Officer, executed 4 separate sales totaling 132,500 shares for $3,476,013.95 on January 8–9, 2026, reducing his stake by 14.8% from 897,688 shares to 765,188 shares. The transactions occurred at prices ($20.13, $24.92, $24.90, $29.13) with a blended average of $26.23, slightly above the current price of $25.03, and notably close to the 52-week high of $26.00 achieved during the 30-day window (+48.5% rally). His prior sales at ELVN exhibit a strong timing pattern: 4 of 4 prior trades showed negative 90-day returns, indicating he has historically sold before subsequent declines. The company reported negative net income of $-20,148,000.00 for its most recent full fiscal year, and with a $1.5B market cap, continues to operate unprofitably. The near-peak execution combined with consistent prior success in timing downturns at this ticker warrants scrutiny of any forward guidance or operational headwinds that may have prompted the liquidation.

CSO Joseph Lyssikatos sold 51,145 shares across 4 transactions for $1,437,585.19 at blended average $28.11

Chief Scientific Officer Joseph Lyssikatos executed 4 separate sales totaling 51,145 shares for $1,437,585.19 on October 8–9, 2024, at prices between $27.96 and $28.52. The sales reduced his holdings by 4.8% from 1,067,180 to 1,016,035 shares, representing a material but not complete exit from his position. The timing is noteworthy: the transactions occurred near the 52-week high of $28.21 and the stock now trades at $26.97 (-4.4% from peak), though the stock has appreciated 15.9% over the prior 30 days and 9.0% over the prior 90 days. Against this backdrop, Enliven remains unprofitable with a net loss of $19,950,000 in its most recent full fiscal year, adding context to why a senior scientist would divest shares despite recent price momentum.